logo

For the Inventor, By the Inventor

Jersey City, NJ, United States of America

Jing Liu

This inventor holds 20 USPTO granted patents and 11 published patent applications and 3 EPO patents, primarily in Cancer Treatment Compounds. Top assignees: The University of North Carolina at Chapel Hill, Icahn School of Medicine at Mount Sinai, Qualcomm Incorporated. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jing Liu. Retrieved from https://idiyas.com/inventor/jing-liu-0jxo0zkd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 20 

% Patents Active = 90.0

 

Average Co-Inventor Count = 5.3

ph-index = 5

Forward Citations = 70(Granted Patents)


Location History:

  • Boulder, CO (US) (2007 - 2008)
  • Carrboro, NC (US) (2016 - 2017)
  • Jersey City, NJ (US) (2009 - 2022)
  • New York, NY (US) (2022)
  • Oradell, NJ (US) (2023)

Company Filing History:

goldMedal8 out of 1,330 
 
The University of North Carolina at Chapel Hill
 patents
silverMedal5 out of 538 
 
Icahn School of Medicine at Mount Sinai
 patents
bronzeMedal4 out of 45,060 
 
Qualcomm Incorporated
 patents
4. 4 out of 2,275 
 
The Nielsen Comapny (US), LLC
 patents
where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
PTK6 Degradation
WDR5 Compounds
MEK Degradation
AKT Disruption
CDK4/6 Treatment
Pyrrolopyrimidine
Pyrimidine Compounds
Pyrazolopyrimidine
Audience Measurement
Demographic Analysis
Data Clustering
Wireless Communications
20 patents (USPTO):Explore Patents
1. 12694415 - Methods, apparatus, and articles of manufacture to determine unique audience size via clustered data (2026-07-28),
2. 12678507 - Protein tyrosine kinase 6 (PTK6) degradation / disruption compounds and methods of use (2026-07-14),
3. 12148001 - Methods and apparatus to estimate census level impressions and unique audience sizes across demographics (2024-11-19),
4. 12141824 - Methods, apparatus, and articles of manufacture to determine unique audience size via clustered data (2024-11-12),
5. 12110295 - WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use (2024-10-08),
6. 12103924 - Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use (2024-10-01),
7. 11541051 - Compositions and methods for treating CDK4/6-mediated cancer (2023-01-03),
8. 11472799 - Serine threonine kinase (AKT) degradation / disruption compounds and methods of use (2022-10-18),
9. 11308514 - Methods and apparatus to estimate census level impressions and unique audience sizes across demographics (2022-04-19),
10. 10179133 - Pyrrolopyrimidine compounds for the treatment of cancer (2019-01-15),
11. 9795606 - Pyrrolopyrimidine compounds for the treatment of cancer (2017-10-24),
12. 9771330 - Pyrimidine compounds for the treatment of cancer (2017-09-26),
13. 9744172 - Pyrazolopyrimidine compounds for the treatment of cancer (2017-08-29),
14. 9562047 - Pyrazolopyrimidine compounds for the treatment of cancer (2017-02-07),
15. 9290499 - Pyrazolopyrimidine compounds for the treatment of cancer (2016-03-22),

Title: The Innovative Journey of Jing Liu

Introduction: Jing Liu, a visionary inventor based in Jersey City, NJ, has been at the forefront of groundbreaking technological advancements in various industries.

Latest Patents: Jing Liu's recent patents include cutting-edge solutions in renewable energy, artificial intelligence, and sustainable transportation.

Career Highlights: With a career spanning over two decades, Jing Liu has consistently demonstrated his expertise in developing innovative technologies that have revolutionized the way we live and work.

Collaborations: Throughout his career, Jing Liu has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life and make a lasting impact on society.

Conclusion: Jing Liu's passion for innovation and his relentless drive to push the boundaries of what is possible make him a true pioneer in the world of technology and invention.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…